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Introduction. Yellow fever is considered a re-emerging disease and is endemic in tropical regions of 
Africa and South America. At present, there are no standardized or commercialized kits available for 
yellow fever virus detection. Therefore, diagnosis must be made by time-consuming routine techniques, 
and sometimes, the virus or its proteins are not detected. Furthermore, co-circulation with other 
flaviviruses, including dengue virus, increases the difficulty of diagnosis. 
Objective. To develop a specific reverse transcriptase-polymerase chain reaction (RT-PCR) and nested 
PCR-based assay to improve the detection and diagnosis of yellow fever virus using both serum and 
fresh tissue samples.
Materials and methods. RT-PCR primers were designed to amplify a short fragment of all yellow fever 
virus genotypes reported. A second set of primers was used in a nested PCR to increase sensitivity. 
Thirty-three clinical samples were tested with the standardized reaction.
Results. The expected amplicon was obtained in 25 out of 33 samples analyzed using this approach, 
and 2 more samples tested positive after a subsequent nested PCR approach.
Conclusion. This improved technique not only ensures the specific detection of a wide range of yellow 
fever virus genotypes but also may increase the sensitivity of detection by introducing a second round 
of amplification, allowing a rapid differential diagnosis between dengue and yellow fever infection, which 
is required for effective surveillance and opportune epidemiologic measures. 
Key words: Yellow fever virus, arboviruses, reverse transcription, polymerase chain reaction, diagnosis, 
epidemiological surveillance.
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Desarrollo de un método de transcripción inversa seguida de reacción en cadena de la 
polimerasa para la detección del virus de la fiebre amarilla
Introducción. La fiebre amarilla se considera una enfermedad reemergente y endémica en regiones 
tropicales de África y Suramérica. Actualmente, no existen estuches estandarizados o comerciales 
disponibles para la detección del virus de la fiebre amarilla y, por lo tanto, el diagnóstico debe hacerse 
mediante técnicas de rutina que consumen mucho tiempo y algunas veces no garantizan la detección 
del virus o de sus proteínas. Además, la cocirculación con otros flavivirus, incluyendo el del dengue, 
hacen el diagnóstico más complicado.
Objetivo. Desarrollar un ensayo específico de amplificación basado en transcripción inversa seguida 
de reacción en cadena de la polimerasa, con el fin de mejorar la detección y el diagnóstico de la fiebre 
amarilla, tanto a partir de suero como de tejido fresco.
Materiales y métodos. Se diseñaron iniciadores específicos para amplificar un fragmento 
conservado del virus de la fiebre amarilla. Un segundo par de iniciadores se usó en una reacción 
de amplificación anidada para incrementar la sensibilidad. Se probaron 33 muestras clínicas con la 
técnica estandarizada.
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Resultados. El amplímero esperado se obtuvo en 25 de las 33 muestras analizadas usando este 
método y 2 más resultaron positivas después de la reacción anidada.
Conclusión. Esta técnica mejorada garantiza la detección de todos los genotipos virales de fiebre 
amarilla y puede incrementar la sensibilidad del ensayo introduciendo una segunda etapa de 
amplificación, lo cual permite el diagnóstico diferencial con infección por dengue y otros flavivirus, lo 
cual es de gran importancia para la vigilancia y la toma de medidas epidemiológicas oportunas.
Palabras clave: virus de la fiebre amarilla, arbovirus, transcripción reversa, reacción en cadena de la 
polimerasa, diagnóstico, vigilancia epidemiológica
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Yellow fever is an arthropod-borne viral disease 
that is clinically indistinguishable from other viral 
hemorrhagic fevers or febrile syndromes that are 
produced by dengue virus, arenavirus, hantavirus, 
West Nile, hepatitis B Virus and infectious diseases 
such as leptospirosis and malaria (1-3).
Yellow fever was one of the most feared diseases 
between the 15th and 19th centuries, and it is still 
a major public health concern in endemic areas, 
with a case fatality rate ranging from 10% to 50% 
of confirmed cases, despite an effective and widely 
available vaccine (3-7). Although asymptomatic 
in some cases, classic illness consists of three 
phases, starting with an unspecific infection period, 
followed by a remission stage in which symptoms 
disappear (1,3). Severe cases are characterized 
by the sudden appearance of high fever that may 
last from hours to days until the intoxication phase, 
when myocardial, renal and hepatic failure with 
jaundice present; progression to fulminate disease 
then occurs, leading to shock and death (1). 
Sporadic cases of yellow fever still occur within 
endemic areas, affecting unvaccinated individuals 
that get close to or enter into tropical forests (3,7-
10). An annual estimate of 200,000 cases and 
30,000 deaths makes it a significant cause of 
morbidity and mortality worldwide (1-3). The official 
number of cases may be underestimated due to a 
lack of detection, misdiagnosis and inaccessibility 
to rural areas and medical facilities. In fact, the real 
incidence could be as high as 5 to 10 times the 
official reports (2,10). In addition, the increasing 
growth of the human population and its forced 
migration, vector re-infestation and redistribution, 
difficulties in transport to some areas and the 
movement of infected travelers may contribute to 
the spread of the disease (3,10). 
The correct and timely diagnosis of yellow fever is 
an important issue, particularly in countries where it 
is endemic. Currently, serological tests include IgM 
antibody capture by enzyme-linked immunosorbent 
assay (MAC-ELISA), hemagglutination inhibition 
(HI), complement fixation (CF) and neutralization (N) 
(1,3). Nevertheless, antibody detection is feasible 
only 5 to 6 days after the onset of symptoms, when 
the severity increases, and there is a chance of 
cross reactivity with other flaviviruses (1). However, 
diagnosis of yellow fever may also be achieved 
during the infection period by the isolation of the 
virus in mosquito cell lines or by genome detection 
through PCR-based methods.
Fatal cases are confirmed by immunohistochemistry 
with monoclonal antibodies in well-conserved fixed 
tissues (1,3,11,12). Virus isolation in mosquito cell 
lines, although specific, takes at least 7-10 days, 
and the sensitivity decreases when few virus 
particles are present in the sample or when toxic 
biliary salts are present in the serum, inhibiting 
cell growth (13). Detection of the virus in the acute 
phase must be specific and sensitive enough to 
confirm the diagnosis; only then can surveillance 
and control campaigns begin. 
To improve and increase the speed of yellow 
fever diagnosis, we designed four novel primers 
for RT-PCR followed by a nested PCR reaction 
to increase sensitivity. In contrast to previously 
reported RT-PCR based methods, genetic diversity 
was considered during the design of these new 
primers, resulting in a highly sensitive reaction 
that is able to amplify any yellow fever genotype 
(3,14). This assay could be easily standardized in 
developing countries, particularly in small cities or 
provinces where disease is endemic, increasing 
the opportunity for diagnosis and improving 
epidemiological surveillance.
Materials and methods
Virus isolates and clinical samples used in this study 
were taken during the acute stage of infection and 
belonged to the sample collection of the Laboratorio 
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de Virología of the Instituto Nacional de Salud, where 
samples are kept at -20 to -70 °C. The yellow fever 
virus strains consisted of 7 lyophilized viral isolates 
obtained between 1964 and 2000. Those viruses 
were reconstituted in 1 mL of sterile phosphate 
buffer saline (PBS) solution prior the extraction of 
RNA. In addition, we processed 10 yellow fever 
sera samples collected between 2004 and 2009 
that were negative for both IgM and viral isolation 
and that had been obtained from febrile cases 5 to 
7 days after the onset of symptoms. Those samples 
were compatible with the case definition of yellow 
fever: illness with a high fever, headache and back 
pain, including cases that presented with vomiting, 
bloody diarrhea, abdominal pain, hematemesis, 
jaundice and epistaxis (1). Travel history to 
endemic zones or other types of exposure was 
always considered. To evaluate the performance 
of the reaction in tissue samples, 13 liver samples 
collected between 2004 and 2009 from fatal cases 
were also tested. Ten of these clinical tissue 
samples were previously confirmed as positive 
for yellow fever by immunohistochemistry. Finally, 
the yellow fever-infected brain tissues from 3 mice 
were used as positive controls.
Thirty complete genome sequences, representing 
all genotypes reported (5 from Africa and 2 from 
the Americas), were obtained from Gene Bank and 
aligned using the ClustalW program included in 
MEGA software (15). Two sets of primers for RT-
PCR and nested PCR were designed to target a 
highly conserved region on the 5´-UTR end of the 
viral genome (figure 1). Primers were analyzed with 
the program Gene Runner 3.0 (Hastings Software 
Inc.) to avoid secondary structures and dimers 
and to calculate melting temperatures. Primer 
sequences were as follows: RT-PCR sense primer 
SYF14, 5´-GCTAATTGAGGTGYATTGGTC-3´, and 
antisense primer ASYF179, 5´-TTARTTTGRTTG 
ACAAGGAGCG-3´; nested PCR sense primer 
NSYF16, 5´-CTAATTGAGGTGYATTGGTCTG-3´ 
and nested antisense primer NASYF94, 5´-
CTGGTCYYTTCTCTGCTAATCG-3´. The name 
of each primer corresponds to its position on the 
genome template.
Viral RNA was extracted from 140 µl of serum 
samples or PBS suspensions of lyophilized virus 
using a QIAamp Viral RNA Mini Kit (QIAGEN, 
Hilden, Germany) and eluted with 40 µl of buffer 
EB. Approximately 1 g of fresh tissue samples was 
treated with 1 mL of lysis buffer (Tris HCL 1 M, SDS 
20%, EDTA 0.5 M pH 8.0, Proteinase K 20 mg/mL, 
RNAase inhibitor 10 U/µl) at 56°C overnight. RNA was 
extracted using Trizol, following the manufacturer’s 
instructions. Briefly, 300 µl of processed tissues 
was mixed with 700 µl of Trizol LS® (Gibco BRL) 
reagent for 5 min; 200 µl chloroform was added, and 
the solution was then mixed for 15 sec by vortexing 
and incubated for 3 min at room temperature. The 
mixture was subsequently centrifuged for 15 min at 
12,000 rpm at 4 °C, and the aqueous phase was 
carefully separated and precipitated with 500 µl cold 
isopropanol for 12 hours at 4 °C. Then, the mixture 
was centrifuged for 10 min at 12,000 rpm at 4 °C, 
and the supernatant was discarded. The RNA was 
washed with 500 µl ethanol and resuspended in 40 
µl of warm water treated with diethylpyrocarbonate 
(DEPC, Sigma) and 20 units of RNAse inhibitor 
(Invitrogen).  
RT-PCR and nested PCR optimal conditions were 
initially estimated to standardize the concentrations 
of Mg2+, dNTPs and primers using yellow fever RNA 
purified from the culture supernatant. The annealing 
temperature was determined by a gradient ranging 
from 50 °C to 60 °C, and serial dilutions of RNA 
(10-1, 10-2, 10-3, 10-4) were used to test the limit of 
detection. Once the best setting for the reaction was 
determined, RT-PCR was performed as follows: 5 µL 
of purified RNA was added to 45 µL of the RT-PCR 
one-step reaction buffer (from the Qiagen One-step 
RT-PCR kit) containing 100 mM of each dNTP, 200 
nM of each designed primer (SYF14, ASYF179) and 
Figure 1. Diagnostic primers were designed at the 5´ UTR (untranslated region) of the yellow fever virus genome. The projection in 
white indicates the positions of PCR primers (bases 14 to 179) and the size of the fragment (166 bp). The projection in pink indicates 
the positions of the nested PCR primers (bases 16 to 94) and the size of the expected amplicon (79 bp).
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2 µl of the enzyme mix. RT-PCR was performed in 
a Perkin Elmer DNA Thermal Cycler 480 (Applied 
Biosystems, Warrington, England), starting with 
a 41 °C incubation for 45 min and then 15 min at 
94 °C, followed for 40 cycles of denaturation at 
94 °C for 30 s, annealing at 55 °C for 1 min and 
extension at 72 °C for 1 min, with a final extension 
at 72 °C for 10 min. PCR products were evaluated 
in a 1.5% ethidium bromide-stained agarose gel. 
Nested PCR was performed by adding 1 µl from 
the original reaction mix of the negative samples to 
49 µl of a reaction mix containing 1X PCR buffer, 
1.5 mM MgCl2, 100 mM of each dNTP, 400 nM of 
each nested primer (NSYF16, NASYF94) and 2.5 
U of DNA recombinant Taq Polymerase (Invitrogen, 
Life Technologies, Carlsbad). The standardized 
reaction included denaturation at 94 °C for 30 s, 
annealing at 57 °C for 4 min, extension at 72 °C for 1 
min and a final extension at 72 °C for 10 min. PCR 
products were then resolved in a 2.0% ethidium 
bromide-stained agarose gel. Finally, to establish 
the specificity of the designed primers, RT-PCR was 
performed using purified dengue RNA (serotypes 
1-4) and St. Louis encephalitis virus under the 
same conditions as described for yellow fever.
Results
The degenerated primers SYF14 and ASYF179 
were designed to target a highly conserved region of 
the non-coding 5’ end. The amplicon corresponded 
to a 166-bp fragment (from base 14 to base 179) 
of the yellow fever virus genome. This amplicon 
was of the expected size and was obtained from 
the three positive controls (mouse brain tissue), the 
7 lyophilized viruses and all fresh tissue samples, 
including those previously confirmed as infected 
with yellow fever by immunohistochemistry (figure 
2). However, the amplicon was obtained from only 
2 out of 10 sera within a clinical frame compatible 
with yellow fever (figure 3). 
The primers NSYF16 and NASYF94 were designed 
to improve the sensitivity of the PCR reaction and 
targeted an internal region of the 166-bp amplicon. 
Nested PCR may increase the chance of virus 
detection in samples with few viral copies and can 
also be used to confirm the first reaction. Nested 
PCR was performed using the first PCR reaction 
from the 8 RT-PCR-negative sera as templates. A 
79-bp amplification product was obtained from 2 
samples (figure 3). The remaining 6 samples were 
taken approximately 5 to 7 days after symptom 
onset, when the virus might not be present. 
Finally, reactions using dengue virus and St. Louis 
encephalitis virus RNA as a template were negative, 
even under nested PCR conditions (figure 3). 
To infer the detection limit of the PCR reaction, serial 
dilutions of extracted RNA (10-1, 10-2, 10-3, 10-4) 
from positive sera (2 samples) and tissue samples 
(13 samples) were tested. Both the tissue samples 
Figure 2. Amplification of yellow fever virus by RT-PCR from different kinds of samples. White arrows point to obtained amplicons 
of the expected size. Lines 1-3: yellow fever-infected mouse brains. Lines 4-10: Lyophilized yellow fever isolates. Lines 11-17: Liver 
tissue samples. Line 18: Molecular Weight Marker (MWM). Line 19: RNA extraction negative control. Line 20: PCR negative control. 
Lines 21-26: Liver tissue samples. Line 27: MWM. Lines 28-31: Dengue virus isolates (types 1 to 4). Line 32: St. Louis encephalitis 
virus.
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and sera were positive up to a -3 dilution of the first 
RT-PCR amplification (figure 4). All dilutions tested 
positive by nested PCR.
Discussion
Colombia is an endemic yellow fever country and 
is surrounded by endemic yellow fever areas. In 
Colombia, there is an enormous risk of receiving 
viruses from infected incoming travelers and a high 
probability of the co-circulation of flavivirus and 
yellow fever genotypes that are not detectable by 
routinely used molecular probes (3,8,10,16-19). 
No molecular epidemiology study of yellow fever 
has been performed in Colombia whose aim was to 
determine the genotype diversity that may result in 
misdiagnosis; therefore, the true number of cases 
may be higher than reported. Dengue fever is also 
endemic, as it is one of the most recurrent febrile 
syndromes in Colombia (3,8,10,20). Co-circulation 
of the four dengue virus serotypes in yellow fever-
endemic regions makes both syndromes easy 
to misdiagnose, especially in cases for which 
symptoms are nonspecific (3,8,10,20). Furthermore, 
co-circulation is a high risk of urbanization because 
both viruses share a common urban vector (7,21). 
Urbanization of yellow fever is a public health threat 
because vaccination is only given to people who are 
travelling to sylvatic areas. Although yellow fever 
vaccination campaigns in Colombia have been 
successful, war conditions and forced displacements 
in endemic regions near forests where viral activity 
has been confirmed have increased the risk of 
transmission and eventual urbanization (3,8,10).
Due to the lack of commercially available kits, 
specific diagnosis of yellow fever may be difficult 
and is often limited to specialized and reference 
Figure 3. Amplification of yellow fever virus by RT-PCR and nested PCR from serum samples. White arrows point to obtained 
amplicons of the expected size. Lines 1-10: Serum samples from compatible yellow fever-infected patients. Line 11: MWM. Lines 
12-19: Nested PCR from the RT-PCR negative sera. Line 20: Nested PCR negative control.
Figure 4. RT-PCR detection limit test. Serial dilutions of extracted RNA were tested by RT-PCR. a. Line 1: MWM. Lines 2-9: RNA 
serial dilutions 10-1, 10-2, 10-3, 10-4) from two serum samples. Lines 10-17: RNA serial dilutions from two tissue samples. b. Line 1: 
MWM. Lines 2-16: RNA serial dilutions from four tissue samples. White arrows point to obtained amplicons of the expected size.
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labs (1). Thus, serologic diagnostic techniques are 
useful after the acute phase when virus is no longer 
present and IgM antibodies become detectable. 
Nevertheless, these antibodies may cross-react 
with other flaviviruses that are genetically and 
antigenically similar to yellow fever, including 
dengue virus, meaning that correct diagnosis is 
even more difficult (1,3).
Viral isolation in mosquito cell lines is a useful 
technique for acute phase samples. However, this 
technique is time consuming, and it is not easy to 
perform in small laboratories. In addition, samples 
for yellow fever virus detection often suffer from 
a lack of proper transportation conditions from 
endemic areas to diagnostic laboratories. Tissue 
or serum samples may pass through several 
freeze-thaw cycles, decreasing the probability 
of virus isolation, causing genome degradation 
or fragmentation and resulting in false-negative 
results, especially in those samples with low viral 
copy numbers (1,3,10). For these reasons, we 
have developed a specific RT-PCR assay with 
novel sets of primers that match a highly conserved 
region of all yellow fever genomes reported to date; 
this assay is thus capable of detecting a wide range 
of genotypes (6,19,21). This conserved genome 
region has a low selective pressure and no role 
in the immune response or the virus-environment 
relationships. Thus, if this sequence is present 
in yellow fever genotypes that have not yet been 
discovered, the use of these two sets of novel 
primers would enable the identification of new 
yellow fever variants. Another advantage of our 
approach is that the amplicon size is small enough 
to appear even in low copy number or degraded 
samples, and when combined with a nested 
PCR reaction, this technique generates a strong 
detectable amplification signal that may increase 
the chance of detection and perhaps the sensitivity 
of the method. Some of the previously published 
primers for yellow fever diagnosis are located in 
variable genome regions that may be exposed 
to selective pressure from the host’s immune 
response, leading to mutation that may reduce the 
chance of detection (3,10). 
In conclusion, we propose a novel specific RT-
PCR-based assay designed to detect all yellow 
fever genotypes circulating worldwide. Although 
further experiments involving the titration of the 
virus or the quantification of RNA should be 
performed to determine the exact sensitivity of 
this method, these preliminary results allow us to 
infer a good limit of detection and; therefore, the 
assay offers an increased chance of identifying 
the viral genome. Conventional PCR is easy to 
perform, even in small laboratories where complex 
techniques such as viral isolation or real time-PCR 
are not feasible. Finally, this technique can be used 
as a complementary tool to improve yellow fever 
surveillance and control strategies because fast 
and specific detection is critical for proper control 
measures – not just to reduce the number of cases 
but also to prevent urbanization of the disease. 
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